Individualized cost-effectiveness analysis

PLoS Medicine

Volumn 8, Issue 7, 2011, Pages

  Ioannidis, John P A ^a   Garber, Alan M ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETORICOXIB; PROTON PUMP INHIBITOR; ROTAVIRUS VACCINE; WARFARIN;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIET THERAPY; DRUG COST; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEART ATRIUM FIBRILLATION; HUMAN; INDIVIDUALIZED COST EFFECTIVENESS ANALYSIS; KNEE PAIN; LAPAROSCOPIC SURGERY; LIFE EXPECTANCY; OSTEOARTHRITIS; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STOMACH FUNDOPLICATION; STRETCHING EXERCISE; DECISION MAKING; METHODOLOGY; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMETRIC;

EID: 79960913503     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001058     Document Type: Article

References (44)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. (1996) Cost-effectiveness in health and medicine Oxford Oxford University Press.
2. Willan AR, (2001) On the probability of cost-effectiveness using data from randomized clinical trials. BMC Med Res Methodol 1: 8.
3. O'Hagan A, Stevens JW, (2002) The probability of cost-effectiveness. BMC Med Res Methodol 2: 5.
4. Kravitz RL, Duan N, Braslow J, (2004) Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 82: 661-687.
5. McLaughlin MJ, HTE Policy Roundtable Panel (2007) Healthcare policy implications of heterogeneity of treatment effects. Am J Med 120 (4) Suppl 1: S32-S35.
6. Greenfield S, Kravitz R, Duan N, Kaplan SH, (2007) Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 120 (4) Suppl 1: S3-S9.
7. Glasziou PP, Irwig LM, (1995) An evidence based approach to individualising treatment. BMJ 311: 1356-1359.
8. Garber AM, (2000) Advances in cost-effectiveness analysis of health interventions. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics, Volume 1 Amsterdam North-Holland pp. 181-221.
9. Mendeloff J, Ko K, Roberts MS, Byrne M, Dew MA, (2004) Procuring organ donors as a health investment: how much should we be willing to spend? Transplanation 78: 1704-1710.
10. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, et al. (2005) The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142: 323-332.
11. Luce R, (2000) Utility of gains and losses: measurement-theoretical and experimental approaches Mahwah (New Jersey) Lawrence Erlbaum Associates.
12. Byrnes JP, Miller DC, Schafer WD, (1999) Gender differences in risk taking: A meta-analysis. Psych Bull 125: 367-383.
13. Elbasha EH, (2005) Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach. Health Econ 14: 457-470.
14. Sapienza P, Zingales L, Maestripieri D, (2009) Gender differences in financial risk aversion and career choices are affected by testosterone. Proc Natl Acad Sci U S A 106: 15268-15273.
15. Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, et al. (2009) Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 151: 612-621.
16. Eckman MH, Rosand J, Greenberg SM, Gage BF, (2009) Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 150: 73-83.
17. Pletcher MJ, Lazar L, Bibbins-domingo K, Moran A, Rodondi N, et al. (2009) Comparing impact and cost-effectiveness of primary prevention strategies for lipid lowering. Ann Intern Med 150: 243-254.
18. Paulden M, Palmer S, Hewitt C, Gilbody S, (2009) Screening for postnatal depression in primary care: cost effectiveness analysis. BMJ 339: b5203 doi:10.1136/bmj.b5203.
19. Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, et al. (2009) Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 339: b2538 doi:10.1136/bmj.b2538.
20. Epstein D, Bojke L, Sculpher MJ, REFLUX Trial Group (2009) Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. BMJ 339: b2576 doi:10.1136/bmj.b2576.
21. Rose J, Hawthorn RL, Watts B, Singer ME, (2009) Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ 339: b3653 doi:10.1136/bmj.b3653.
22. Barton GR, Sach TH, Jenkinson C, Doherty M, Avery AJ, et al. (2009) Lifestyle interventions for knee pain in overweight and obese adults aged > or = 45: economic evaluation of randomised controlled trial. BMJ 339: b2273.
23. Laska EM, Meisner M, Siegel C, (1997) Statistical inference for cost-effectiveness ratios. Health Econ 6: 229-242.
24. Briggs A, Fenn P, (1997) Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios'. Health Econ 6: 491-495.
25. Ioannidis JP, Lau J, (1997) The impact of high-risk patients on the results of clinical trials. J Clin Epidemiol 50: 1089-1098.
26. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA, (2010) Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 11: 85.
27. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, et al. (1995) Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 332: 1418-1424.
28. Gilbody S, Wilson P, Watt I, (2005) Benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care 14: 246-250.
29. Wright CF, Hall A, Zimmern RL, (2011) Regulating direct-to-consumer genetic tests: What is all the fuss about? Genet Med 13: 295-300.
30. Cohen JP, Paquette C, Cairns CP, (2005) Switching prescription drugs to over the counter. BMJ 330: 39-41.
31. Nease RF Jr, Owens DK, (1994) A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Med Decis Making 14: 382-392.
32. Gage BF, Cardinalli AB, Owens DK, (1998) Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 29: 1083-1091.
33. Gafni A, Birch S, Mehrez A, (1993) Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted live-year). J Health Econ 12: 325-339.
34. Mehrez A, Gafni A, (1989) Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 9: 142-149.
35. Mehrez A, Gafni A, (1991) The healthy-years equivalents: how to measure them using the standard gamble approach. 11: 140-146.
36. Hutchings A, Durand MA, Grieve R, Harrison D, Rowan K, et al. (2009) Evaluation of modernisation of adult critical care services in England: time series and cost effectiveness analysis. BMJ 339: b4353 doi:10.1136/bmj.b4353.
37. Kim JJ, Goldie SJ, (2009) Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339: b3884 doi:10.1136/bmj.b3884.
38. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK, (2009) Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med 151: 829-839.
39. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, et al. (2006) Bias in published cost effectiveness studies: systematic review. BMJ 332: 699-703.
40. Miners AH, Garau M, Fidan D, Fischer AJ, (2005) Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ 330: 65.
41. Polyzos NP, Valachis A, Mauri D, Ioannidis JPA, (2011) Sponsorship bias in assumptions of cost-effectiveness analysis: the diagnostic accuracy of the Pap test. CMAJ In press.
42. Hoch JS, Dewa CS, (2007) Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters. Pharmacoeconomics 25: 807-816.
43. O'Brien BJ, Sculpher MJ, (2000) Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules. Med Care 38: 460-468.
44. Owens DK, Qaseem A, Chou R, Shekelle P, Clinical Guidelines Committee of the American College of Physicians (2011) High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med 154: 174-180.